DDInter496 DDInter899
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Delavirdine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Delavirdine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Delavirdine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Reverse Transcriptase Inhibitors
Delavirdine {u} (Compound) causes {v} (Side Effect) Paralysis
Delavirdine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teniposide
Delavirdine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Delavirdine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Delavirdine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pantoprazole
Delavirdine {u} may lead to a major life threatening interaction when taken with {v} Midostaurin
Delavirdine {u} may lead to a major life threatening interaction when taken with {v} Terfenadine
Delavirdine (Compound) treats acquired immunodeficiency syndrome (Disease)
Delavirdine (Compound) binds CYP3A7-CYP3A51P (Gene)
Delavirdine (Compound) is included by Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Delavirdine (Compound) causes Paralysis (Side Effect)
Delavirdine may cause a minor interaction that can limit clinical effects when taken with Teniposide
Delavirdine may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole
Delavirdine may lead to a major life threatening interaction when taken with Midostaurin
Delavirdine may lead to a major life threatening interaction when taken with Terfenadine